Fluorinated tracers for imaging cancer with positron emission tomography

Couturier, O.; Luxen, André; Chatal, Jean‐François; Vuillez, Jean‐Philippe; Rigo, Pierre; Hustinx, Roland

doi:10.1007/s00259-004-1607-9

Cited by 119 publications

(75 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The tracer is routinely available at our center, and efforts are being made to develop a fully automated procedure. Although the uptake mechanisms of 11 C-MET and 18 F-TYR differ, both compounds are markers of amino acid metabolism, with similar clinical results in neurooncology (12). Thanks to their longer physical half-life, as compared with that of 11 C, fluorinated compounds can be used in nuclear medicine departments distant from a cyclotron.…”

mentioning

confidence: 95%

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Rutten¹,

Cabay²,

Withofs³

et al. 2007

Journal of Nuclear Medicine

View full text Add to dashboard Cite

Precise delineation of the shape of skull base meningiomas is critical for their treatment and follow-up but is often difficult using conventional imaging such as CT and MRI. We report our results with PET/CT and 2-18 F-fluoro-L-tyrosine ( 18 F-TYR), a marker of amino acid transport, as part of the yearly follow-up of irradiated patients. Methods: Eleven patients (mean age, 56.5 y) with skull base meningiomas (n 5 13 lesions) previously irradiated were included. All patients received 300 MBq of 18 F-TYR and were imaged after 30 min of uptake, using a dedicated PET/CT system. The images were first visually examined, and regions of interest (ROI) were then placed over the transaxial PET slice showing the highest uptake. Another ROI was placed over the normal parietal cortex. Tumor-to-cortex activity ratios were obtained by dividing the maximum pixel value in the tumor ROI by the maximum pixel value in the cortex ROI. The PET/CT images were compared with the MR images obtained as part of routine followup. Results: Accumulation of the tracer was higher in all meningiomas than in the surrounding tissue. The tumor-to-cortex activity ratio was 2.53 6 0.35 (range, 1.3-6). Nonneoplastic tissue such as hyperemic cavernous sinus did not take up the radionuclide and was therefore easily distinguished from the meningioma. The 18 F-TYR anomalies completely overlapped with the MR image in 54% of the tumors, extended beyond the MRI lesion in 38% of the tumors, and were smaller in 8% of the tumors. Conclusion: Meningiomas of the skull base are clearly visualized using 18 F-TYR PET/CT, even after irradiation. In addition to MRI, 18 F-TYR PET/CT images may contribute to the evaluation, delineation, and follow-up of these tumors.

show abstract

mentioning

confidence: 95%

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Rutten¹,

Cabay²,

Withofs³

et al. 2007

Journal of Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, F-18-labeled synthetic amino acids have gained great interest [17,18]. The radiolabeled synthetic amino acids can be classified into two groups: aromatic amino acids and alicyclic amino acids.…”

Section: Synthetic Amino Acidsmentioning

confidence: 99%

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Zhu

Shim

2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission tomography (PET) has been widely used in the clinical management of patients with cancer. Nuclear imaging provides biological information at the cellular, subcellular, and molecular level in living subjects with noninvasive procedures. In particular, PET imaging takes advantage of traditional diagnostic imaging techniques and introduces positron-emitting probes to determine the expression of indicative molecular targets at different stages of cancer. 18 F-fluorodeoxyglucose ( 18 F-FDG), the only FDA approved oncological PET tracer, has been widely utilized in cancer diagnosis, staging, restaging, and even monitoring response to therapy; however, 18 F-FDG is not a tumor-specific PET tracer. Over the last decade, many promising tumor-specific PET tracers have been developed and evaluated in preclinical and clinical studies. This review provides an overview of the current non-18 F-FDG PET tracers in oncology that have been developed based on tumor characteristics such as increased metabolism, hyperproliferation, angiogenesis, hypoxia, apoptosis, and tumor-specific antigens and surface receptors.

show abstract

“…(Couturier et al, 2004). Il pourrait alors également prédire l'efficacité d'un traitement en indiquant son impact sur la vitesse de prolifération de la tumeur.…”

Section: Perspectives De Développement Des Traceurs Fluorés Et Autresunclassified

Radioprotection associée aux nouvelles évolutions, diagnostiques et thérapeutiques, en médecine nucléaire

Aubert

Chatal

2006

Radioprotection

View full text Add to dashboard Cite

ArticleRadioprotection associée aux nouvelles évolutions, diagnostiques et thérapeutiques, en médecine nucléaire . Regarding exposure nuclear medicine personnel, the amount of radioactivity used for therapeutic purposes is currently limited to 740 MBq, which requires that the patient be kept in a shielded room. Radiation exposure can be roughly estimated by measuring the exposure rate (in µSv/h) delivered at a distance of 1 meter from a source of one MBq. When considering both the exposure rate and half-life, it appears that similar doses of iron-52, yttrium-86, and iodine-124 deliver a high dose rate immediately after injection and during the following few hours. Current regulations on environmental exposure limit radioactivity levels in hospital sewage outfalls to 1000 Bq/L, for technetium 99m, and 100 Bq/L, for iodine-131. Forthcoming regulations for other radionuclides should not be established solely based on general rules such as the 100 Bq/L limit. Impact studies similar to those required in the nuclear industry, should be conducted.

show abstract

Fluorinated tracers for imaging cancer with positron emission tomography

Cited by 119 publications

References 186 publications

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Current Molecular Imaging Positron Emitting Radiotracers in Oncology

Radioprotection associée aux nouvelles évolutions, diagnostiques et thérapeutiques, en médecine nucléaire

Contact Info

Product

Resources

About